within Pharmacolibrary.Drugs.ATC.N;

model N02BA07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 0.16666666666666666,
    adminDuration  = 600,
    adminMass      = 0.25,
    adminCount     = 1,
    Vd             = 0.0009,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Ethenzamide is a non-opioid analgesic and antipyretic drug historically used for relief of pain and fever. It acts primarily by inhibiting the synthesis of prostaglandins. The drug has been used mainly in Japan and several other countries, often in combination with caffeine and acetaminophen. It is not widely used or approved in many countries today.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adults after a single oral dose, as no published human compartmental PK models are available.</p><h4>References</h4><ol><li>Takato Nikaido, Chikashi Maruyama, Minako Hamanaka, Chiharu Yamaguchi, Yukiko Fujimaru, Yutaka Nakanishi, Toshiki Asano, Akiko Takaoka,Ethenzamide Exerts Analgesic Effect at the Spinal Cord via Multiple Mechanisms of Action Including the 5HT,Biological & pharmaceutical bulletin,2020<a href='https://pubmed.ncbi.nlm.nih.gov/32147623/'>https://pubmed.ncbi.nlm.nih.gov/32147623/</a></li><li>J Shibasaki, R Konishi, M Takemura, E Fukushima, J Nakamura, H Sasaki,Comparison of the first-pass metabolism of ethenzamide and salicylamide in rats.,Journal of pharmacobio-dynamics,1984<a href='https://pubmed.ncbi.nlm.nih.gov/6530645/'>https://pubmed.ncbi.nlm.nih.gov/6530645/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N02BA07;
